Related Experiment Video
Updated: May 12, 2026
13:34
Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
Published on: March 17, 2014
11.3K
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and
Shai Shimony1, Marlise R Luskin1, Naseema Gangat2
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
American Journal of Hematology
|June 17, 2025
Summary
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive cancer. Treatment involves chemotherapy or tagraxofusp, with stem cell transplant for eligible patients.
Area of Science:
- Hematology
- Oncology
- Dermatology
Background:
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy.
- Characterized by violaceous tumors on sun-exposed skin, it affects multiple organs.
- Typically seen in older adult men, but can affect younger individuals.
Purpose of the Study:
- To summarize the key aspects of Blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- To outline diagnostic criteria, treatment strategies, and prognostic factors.
Main Methods:
- Diagnosis relies on biopsy and immunophenotyping (CD123, CD4, CD56).
- Treatment options include chemotherapy or tagraxofusp (a CD123-targeted therapy).
- Hematopoietic allogeneic stem cell transplantation is recommended for consolidation.
Main Results:
- Median overall survival is 18-24 months.
- Risk factors for poor prognosis include advanced age, bone marrow involvement, and genetic abnormalities.
- Central nervous system involvement requires mandatory assessment and treatment.
Conclusions:
- BPDCN necessitates a multidisciplinary approach involving hematology, oncology, and dermatology.
- Early diagnosis and appropriate therapy, including stem cell transplantation, are crucial.
- Ongoing research aims to improve outcomes for this rare neoplasm.
